Affordable Access

deepdyve-link
Publisher Website

A modular and controllable T cell therapy platform for acute myeloid leukemia

Authors
  • Benmebarek, Mohamed-Reda1
  • Cadilha, Bruno L.1
  • Herrmann, Monika2
  • Lesch, Stefanie1
  • Schmitt, Saskia2
  • Stoiber, Stefan1
  • Darwich, Abbass3
  • Augsberger, Christian2
  • Brauchle, Bettina2, 4
  • Rohrbacher, Lisa2, 4
  • Oner, Arman1
  • Seifert, Matthias1
  • Schwerdtfeger, Melanie1
  • Gottschlich, Adrian1
  • Rataj, Felicitas1
  • Fenn, Nadja C.2
  • Klein, Christian5
  • Subklewe, Marion2, 4, 6
  • Endres, Stefan1, 6, 7
  • Hopfner, Karl-Peter8
  • And 1 more
  • 1 Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany
  • 2 Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany
  • 3 Humanitas Clinical and Research Center,
  • 4 Gene Center, LMU Munich,
  • 5 Roche Innovation Center Zurich,
  • 6 German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
  • 7 German Research Center for Environmental Health (HMGU),
  • 8 Gene Center, LMU,
Type
Published Article
Journal
Leukemia
Publisher
Springer Nature
Publication Date
Jan 07, 2021
Pages
1–15
Identifiers
DOI: 10.1038/s41375-020-01109-w
PMID: 33414484
PMCID: PMC7789085
Source
PubMed Central
Keywords
License
Unknown

Abstract

Modular platform enabling controlled targeting of AML by SAR-transduced T cells in combination with tandem scFv constructs. Efficient lysis of primary AML blasts in vitro and strong antitumoral effects and T cell persistence in xenograft models.

Report this publication

Statistics

Seen <100 times